Brother of the regulator of imprinted sites (BORIS) is a putative new oncogene that is classified as a cancer germline gene; however, its role in the development of cancer is unclear. This study investigated the expression of BORIS in lung cancer and its clinical implications. Methods: The expression of BORIS messenger ribonucleic acid (mRNA) in the sputum of 100 patients with lung cancer (50 with squamous cell carcinoma, 36 with adenocarcinoma, and 14 with small-cell carcinoma) was evaluated by reverse transcription polymerase chain reaction. Results: The overall expression rate of BORIS in patients with lung cancer was 36.0%: 19 of 50 squamous cell carcinomas (38.0%), 13 of 36 adenocarcinomas (36.1%), and 4 of 14 (28.6%) small-cell carcinomas. There was no significant difference in the BORIS expression according to age, gender, or histologic type. However, the mRNA expression of BORIS was significantly related to the pathologic cancer stage (p=0.004) and lymph node metastasis (p=0.001). The expression of the melanoma antigen gene family A1-6 was not associated with the expression of BORIS. Conclusion: Our results suggest that the expression of BORIS might be a negative prognostic factor in lung cancers and implicate BORIS as a molecular target for immunotherapy.
INTRODUCTION
Despite advances in diagnostic and therapeutic modalities against lung cancer, little improvement in the prognostic outcome has been accomplished. Therefore, new screening methods and therapeutic approaches, including immunotherapy, are needed for the management of patients with lung cancer.
Cancer germline (CG) or cancer testis antigen (CTA) genes are genes that are normally expressed in germline cells but can be expressed in various tumors as a result of demethylation [1, 2] . These proteins have been considered to be targets for immunotherapy and to be prognostic factors because their expression is associated with the characteristic features of the neoplastic phenotype, including invasiveness, immune evasion, and metastatic capacity [1] . Brother of the regulator of imprinted sites (BORIS) is a newly described autosomal CG or Values are presented as number or number (mean age).
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CTA that has been proposed to function as an oncogene in human cancer through the dysregulation of the cancer epigenome [1] . However, its role during oncogenesis and the clinical implications of its expression are not clear [2] .
The melanoma antigen gene family A (MAGEA) consists of several subtypes, including MAGEA1 to MAGEA12, that are also categorized as CG antigens [3] . During the past several years, the expression of MAGEA genes has been studied for application in cancer diagnosis and targeted immunotherapy [3] [4] [5] . The aim of this study was to investigate the expression of BORIS in the sputum of patients with lung cancer and its clinical implications.
METHODS

1) Materials
The induced sputum of 100 patients with primary lung (Table 1) . Table 2 .
2) Methods
3) Statistical analysis
Statistical analysis was performed using SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA). Categorical variables were compared by Fisher's exact test and chi-square analysis with the Yates correction. Differences were considered significant if the p-value was less than 0.05.
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− 381 − Fig. 1 . Detection of brother of the regulator of imprinted sites messenger ribonucleic acid in sputum of patients with lung cancer. M, size marker (273bp); 1-6, squamous cell carcinoma; 7-10, small-cell carcinoma; 11, 12, adenocarcinoma; bp, base pairs. Fig. 2 . Detection of melanoma antigen gene family A1-6 messenger ribonucleic acid in sputum of patients with lung cancer. M, size marker (490bp); 1-6, squamous cell carcinoma; 7-10, small-cell carcinoma; 11, 12, adenocarcinoma; bp, base pairs.
RESULTS
The overall expression rate of BORIS in our patients with lung cancer was 36.0% (36/100) ( The expression rate of MAGEA1-6 was 76% (76/100) for all lung cancer patients (Fig. 2) . MAGE was expressed in 90% (45/50) of the patients with squamous cell carcinoma, 57.1% (8/14) of the patients with small-cell carcinoma, and 36.1% (13/36) of the patients with adenocarcinoma. The expression rate in squamous cell carcinoma was significantly higher than that in the other two histologic types (p=0.001).
There was no significant difference in the MAGEA1-6 expression according to the pathologic cancer stage and lymph node metastasis. There was no significant correlation between the expression of BORIS and the expression of MAGE. CGs such as MAGEA [3] [4] [5] [6] [7] .
BORIS, a novel member of the CG family, is suspected to be a new oncogene with unknown functions [2, 8] and is considered a potential molecular target for cancer immunotherapy [8] . In our study, the expression rate of BORIS in lung cancer patients was 36%. The expression of BORIS was not significantly different according to age, gender, or histologic type but was significantly associated with the pathologic cancer stage (p=0.004) and lymph node metastasis (p=0.001).
The expression of MAGEA1-6 was not associated with the expression of BORIS.
In the case of breast cancer, the expression rate of BORIS was reported to be 70.7% [9] and BORIS expression was detected in 73 of the 95 (77%) endometrial cancers and 24 of the 31 (77%) uterine-mixed mesodermal tumors [10] . BORIS was also detected in 27% (n=63) of the melanoma tissue samples [11] . BORIS expression was also reported in ovarian cancer patients with advanced stage disease [12] . These re- MAGE or other proto-oncogenes [13] . Moreover, the aberrant expression of BORIS is associated with the up-regulation of candidate proto-oncogenes in multiple human malignancies [13, 14] . The expression of BORIS might explain how the expression of the human retinoblastoma-related Rb2/p130 gene accelerates the progression and recurrence of lung tumors after treatment [14] . However, findings on the regulatory role of BORIS in the expression of other genes are inconclusive.
A previous study reported that CTA expression is dependent on BORIS and BORIS regulates the CTA gene expression through methylation-dependent and -independent mechanisms [15] . In addition, another study suggested that the expression of BORIS and MAGE was not correlated in tumors expressing low levels of BORIS such as melanoma [11] . Our results suggest a similar low expression rate of BORIS (36.0%) in lung cancer. Moreover, the expression of BORIS was not associated with the expression of MAGEA1-6 in our patients.
Our study revealed that lymph node metastasis and pathologic cancer stage were significantly related to the expression of BORIS. This is supported by a report that the BORIS expression is significantly associated with the lymph node metastasis and is an independent poor prognostic factor in esophageal cancer [16] .
BORIS has been studied as a target of immunotherapy [17] , and our data suggest that 36% of the patients with lung cancer could be considered candidates for immunotherapy using BORIS. However, further studies with larger populations and survival analyses are needed to reach a solid conclusion about the prognostic implications of the BORIS expression in lung cancer.
1) Limitations of this study
Finally, we note a few limitations of this study. We did not quantify the expression of BORIS and MAGE mRNA, while we presented them in the sputum of patients with lung
cancer. The survival analysis according to BORIS was not performed. In addition, if the sample size were larger, the study on non-small-cell lung carcinoma would have been more homogenous and valuable. Therefore, a more complete analysis of BORIS, including the survival analysis in larger sample sets, would be the next step to investigate the precise clinical impact of BORIS in the case of lung cancers.
2) Conclusion
BORIS could be a molecular target for immunotherapy in the 36% of patients with lung cancers that express the BORIS gene. The expression of BORIS in sputum might be a prognostic factor associated with a higher pathologic cancer stage and lymph node metastasis.
